Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again

NDA FilingEbvalloPositive

AI Analysis

Summary

Atara Biotherapeutics and Pierre Fabre Pharmaceuticals are resubmitting Ebvallo for posttransplant complication treatment after the FDA reversed its previous guidance following Commissioner Marty Makary's exit, joining other previously rejected therapies now being reconsidered.

Outcome Details

Resubmission after previous FDA rejections; FDA guidance reversed after Commissioner Marty Makary's exit

Importance:7/10

Sentiment:

0.30

cell therapyFDA resubmissionregulatory reversalposttransplant complication

Related Companies

$ATRA

Read the original article

Published by BioSpace on September 30, 2026 2:52 PM

Read Original